商业化-话题@MedSci

#商业化#

27篇内容 | 933人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1506773, encodeId=0c641506e7316, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, objectType=article, longId=218421, objectId=20732184217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20732184217a, replyNumber=0, likeNumber=33, createdTime=2021-10-13, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20732184217a, moduleTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20732184217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506772, encodeId=97381506e72c5, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作, objectType=article, longId=216366, objectId=36882163668a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36882163668a, replyNumber=0, likeNumber=36, createdTime=2021-08-28, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36882163668a, moduleTitle=万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36882163668a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506771, encodeId=458f1506e7153, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, objectType=article, longId=215484, objectId=c5ca215484fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ca215484fd, replyNumber=0, likeNumber=34, createdTime=2021-08-11, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ca215484fd, moduleTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5ca215484fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506770, encodeId=854e1506e702b, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, objectType=article, longId=211060, objectId=0efc211060e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0efc211060e6, replyNumber=0, likeNumber=46, createdTime=2021-05-11, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0efc211060e6, moduleTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0efc211060e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506769, encodeId=07cb1506e69e2, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=东曜药业：深度布局抗肿瘤ADC药物的研发及商业化, objectType=article, longId=209505, objectId=cd5120950549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd5120950549, replyNumber=0, likeNumber=45, createdTime=2021-04-05, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd5120950549, moduleTitle=东曜药业：深度布局抗肿瘤ADC药物的研发及商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd5120950549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506768, encodeId=36651506e68d1, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔, objectType=article, longId=200585, objectId=04ad2005856e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04ad2005856e, replyNumber=0, likeNumber=45, createdTime=2020-09-13, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04ad2005856e, moduleTitle=技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04ad2005856e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506767, encodeId=50f11506e67d5, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素, objectType=article, longId=200169, objectId=85b120016913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b120016913, replyNumber=0, likeNumber=36, createdTime=2020-09-04, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b120016913, moduleTitle=刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b120016913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506766, encodeId=fec51506e667d, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响 , objectType=article, longId=194834, objectId=0fc7194834a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fc7194834a2, replyNumber=0, likeNumber=33, createdTime=2020-05-29, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fc7194834a2, moduleTitle=Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fc7194834a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506765, encodeId=0e761506e65d6, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化, objectType=article, longId=185938, objectId=cf49185938ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf49185938ae, replyNumber=0, likeNumber=25, createdTime=2020-01-10, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf49185938ae, moduleTitle=针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf49185938ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506764, encodeId=1ccc1506e6447, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=沃比医疗与德国Phenox达成全面商业化合作，惠及全球脑卒中患者, objectType=article, longId=184659, objectId=f9e9184659cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9e9184659cd, replyNumber=0, likeNumber=32, createdTime=2019-12-14, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9e9184659cd, moduleTitle=沃比医疗与德国Phenox达成全面商业化合作，惠及全球脑卒中患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9e9184659cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506763, encodeId=a5be1506e636c, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=超10款产品获批，商业化待定，干细胞治疗是挣钱利器还是救世英雄？, objectType=article, longId=183432, objectId=e1c118343277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1c118343277, replyNumber=0, likeNumber=28, createdTime=2019-11-24, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1c118343277, moduleTitle=超10款产品获批，商业化待定，干细胞治疗是挣钱利器还是救世英雄？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1c118343277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506762, encodeId=c7271506e6269, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=德国模式+张江制造：跨国药企在华生物制药商业化合同生产（CMO）服务平台亮相进博会, objectType=article, longId=182498, objectId=46e01824984a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46e01824984a, replyNumber=0, likeNumber=38, createdTime=2019-11-08, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46e01824984a, moduleTitle=德国模式+张江制造：跨国药企在华生物制药商业化合同生产（CMO）服务平台亮相进博会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46e01824984a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506761, encodeId=c89e1506e61e3, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=先声药业与JWP宣布在中国联合开发和商业化抗痛风新药, objectType=article, longId=180180, objectId=c84118018060, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84118018060, replyNumber=0, likeNumber=30, createdTime=2019-09-29, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84118018060, moduleTitle=先声药业与JWP宣布在中国联合开发和商业化抗痛风新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84118018060)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506760, encodeId=d5fa1506e60a3, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=受制于支付方和服务体系健康管理商业化的挑战, objectType=article, longId=166971, objectId=77401669e183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77401669e183, replyNumber=0, likeNumber=35, createdTime=2019-05-29, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77401669e183, moduleTitle=受制于支付方和服务体系健康管理商业化的挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77401669e183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506759, encodeId=9be91506e596a, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, objectType=article, longId=159211, objectId=6a41159211ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a41159211ca, replyNumber=0, likeNumber=26, createdTime=2019-01-31, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a41159211ca, moduleTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a41159211ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506758, encodeId=3cdc1506e58b7, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权, objectType=article, longId=154875, objectId=03751548e558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03751548e558, replyNumber=0, likeNumber=31, createdTime=2018-12-02, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03751548e558, moduleTitle=再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03751548e558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506757, encodeId=31261506e575e, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=“基因魔剪”CRISPR商业化加速，细胞治疗成**站, objectType=article, longId=141991, objectId=adcf1419919b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adcf1419919b, replyNumber=0, likeNumber=38, createdTime=2018-07-01, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adcf1419919b, moduleTitle=“基因魔剪”CRISPR商业化加速，细胞治疗成**站, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adcf1419919b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506756, encodeId=63841506e564c, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=微生物组学商业化突破之困, objectType=article, longId=128561, objectId=a1d91285617b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d91285617b, replyNumber=0, likeNumber=35, createdTime=2018-02-03, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d91285617b, moduleTitle=微生物组学商业化突破之困, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d91285617b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506755, encodeId=5ecc1506e5506, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=Circ Cardiovasc Qual Outcomes：3种非专利降压药商业化对不良事件有何影响？, objectType=article, longId=120812, objectId=463112081258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463112081258, replyNumber=0, likeNumber=44, createdTime=2017-11-22, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463112081258, moduleTitle=Circ Cardiovasc Qual Outcomes：3种非专利降压药商业化对不良事件有何影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463112081258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506754, encodeId=97d91506e54a6, content=<a href='/topic/show?id=afce40064d1' target=_blank style='color:#2F92EE;'>#商业化#</a>, objectTitle=J Endod：2种商业化古塔胶加热器的充填器表面温度研究, objectType=article, longId=115120, objectId=eda1115120d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda1115120d3, replyNumber=0, likeNumber=26, createdTime=2017-10-04, rootId=0, userName=yeaweam, userId=8b549798360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda1115120d3, moduleTitle=J Endod：2种商业化古塔胶加热器的充填器表面温度研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda1115120d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

商业化

2020-05-29

yeaweam (审核中...)

前往app查看评论内容

#商业化#

武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化

2021-10-13

yeaweam (审核中...)

前往app查看评论内容

#商业化#

万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作

2021-08-28

yeaweam (审核中...)

前往app查看评论内容

#商业化#

和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化

2021-08-11

yeaweam (审核中...)

前往app查看评论内容

#商业化#

2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化

2021-05-11

yeaweam (审核中...)

前往app查看评论内容

#商业化#

东曜药业：深度布局抗肿瘤ADC药物的研发及商业化

2021-04-05

yeaweam (审核中...)

前往app查看评论内容

#商业化#

技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔

2020-09-13

yeaweam (审核中...)

前往app查看评论内容

#商业化#

刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素

2020-09-04

yeaweam (审核中...)

前往app查看评论内容

#商业化#

Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#商业化#

针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA，Curis收购抗VISTA抗体并准备将其商业化

2020-01-10

yeaweam (审核中...)

前往app查看评论内容

#商业化#

沃比医疗与德国Phenox达成全面商业化合作，惠及全球脑卒中患者

2019-12-14

yeaweam (审核中...)

前往app查看评论内容

#商业化#

超10款产品获批，商业化待定，干细胞治疗是挣钱利器还是救世英雄？

2019-11-24

yeaweam (审核中...)

前往app查看评论内容

#商业化#

德国模式+张江制造：跨国药企在华生物制药商业化合同生产（CMO）服务平台亮相进博会

2019-11-08

yeaweam (审核中...)

前往app查看评论内容

#商业化#

先声药业与JWP宣布在中国联合开发和商业化抗痛风新药

2019-09-29

yeaweam (审核中...)

前往app查看评论内容

#商业化#

受制于支付方和服务体系健康管理商业化的挑战

2019-05-29

yeaweam (审核中...)

前往app查看评论内容

#商业化#

Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利

2019-01-31

yeaweam (审核中...)

前往app查看评论内容

#商业化#

再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权

2018-12-02

yeaweam (审核中...)

前往app查看评论内容

#商业化#

“基因魔剪”CRISPR商业化加速，细胞治疗成**站

2018-07-01

yeaweam (审核中...)

前往app查看评论内容

#商业化#

微生物组学商业化突破之困

2018-02-03

yeaweam (审核中...)

前往app查看评论内容

#商业化#

Circ Cardiovasc Qual Outcomes：3种非专利降压药商业化对不良事件有何影响？

2017-11-22

yeaweam (审核中...)

前往app查看评论内容

#商业化#

J Endod：2种商业化古塔胶加热器的充填器表面温度研究

2017-10-04

科室
- - 订阅+
  - 更多科室
工具
服务